Visceral Leishmaniasis–Associated Hemophagocytic Lymphohistiocytosis in a Patient With Crohn’s Disease in Therapy With Anti‐TNFα: A Challenging Diagnostic Case Report
Case Reports in Gastrointestinal Medicine · 2026-01 · 2026 (1)
DOI: 10.1155/crgm/6403158 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Gastrointestinal Medicine, online erschienen am 28.07.2026. Verfasst von Caterina Pelligra und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, unimi.it. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hemophagocytic lymphohistiocytosis (HLH) is a rare yet life‐threatening hyperinflammatory syndrome, increasingly reported in patients with inflammatory bowel disease (IBD) receiving biologic therapy. While Epstein–Barr virus and cytomegalovirus represent the most frequent infectious triggers, visceral leishmaniasis (VL) is extremely uncommon and may be easily ignored outside endemic areas. Case Presentation We report the case of a 31‐year‐old man with Crohn’s disease treated with escalated anti‐TNFα therapy who presented with persistent fever, pancytopenia, hyperferritinemia, hypertriglyceridemia, and progressive systemic inflammation. Both infectious and oncologic workups were initially inconclusive. PET/CT showed splenomegaly, diffuse splenic, and bone marrow hypermetabolism, raising suspicion for a lymphoproliferative disorder; however, bone marrow aspirate revealed systemic inflammation and hemophagocytosis, suggesting HLH and detected intracellular amastigotes consistent with Leishmania spp., subsequently confirmed by serology. Liposomal amphotericin B prompted rapid clinical and biochemical improvement, with complete resolution of HLH. Anti‐TNFα was discontinued and replaced with anti–IL‐12/23 therapy to maintain IBD control while minimizing infectious risk.
Conclusion
In patients receiving anti‐TNF therapy who present with persistent fever, cytopenias, hyperferritinemia, and unexplained systemic inflammation, HLH should be promptly investigated. Early bone marrow examination may facilitate diagnosis by revealing both hemophagocytosis and Leishmania amastigotes, enabling timely treatment. Following resolution of infection, transition to a biologic with a different mechanism of action, such as anti–IL‐12/23 therapy, may represent a reasonable strategy for long‐term IBD management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy, unimi.it.
- Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Gastroenterology and Endoscopy Unit, Milan, Italy, policlinico.mi.it.
ORCID-Profile: Caterina Pelligra, Lorenzo Bolis, Andrea Costantino, Maurizio Vecchi
Zitieren
APA
Pelligra, C., Bolis, L., Costantino, A., & Vecchi, M. (2026). Visceral Leishmaniasis–Associated Hemophagocytic Lymphohistiocytosis in a Patient With Crohn’s Disease in Therapy With Anti‐TNFα: A Challenging Diagnostic Case Report. Case Reports in Gastrointestinal Medicine, 2026(1). https://doi.org/10.1155/crgm/6403158
Vancouver
Pelligra C, Bolis L, Costantino A, Vecchi M. Visceral Leishmaniasis–Associated Hemophagocytic Lymphohistiocytosis in a Patient With Crohn’s Disease in Therapy With Anti‐TNFα: A Challenging Diagnostic Case Report. Case Reports in Gastrointestinal Medicine. 2026;2026(1). doi:10.1155/crgm/6403158
BibTeX
@article{Pelligra2026,
author = {Pelligra, Caterina and Bolis, Lorenzo and Costantino, Andrea and Vecchi, Maurizio},
title = {Visceral Leishmaniasis–Associated Hemophagocytic Lymphohistiocytosis in a Patient With Crohn’s Disease in Therapy With Anti‐TNFα: A Challenging Diagnostic Case Report},
journal = {Case Reports in Gastrointestinal Medicine},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/crgm/6403158}
}
EUVIMED